Abstract
MicroRNAs (miRNAs) are small, non-coding RNAs that can post-transcriptionally regulate gene expression via messenger RNA (mRNA) targeting. During the past few years several miRNA groups emerged as critical components of developmental and pathological processes, among them being cancer. In colorectal cancer (CRC) specifically, numerous miRNA molecules have been identified up- or downregulated functioning as tumor-specific markers with oncogenic and tumor-suppressive properties. Their dysregulation impacts impaired cellular processes such as cell proliferation, apoptosis, angiogenesis, invasion and metastasis. The detection of extracellular miRNAs in plasma and fecal samples of CRC patients tends to provide novel, non-invasive biomarkers in favor of CRC diagnosis and, at the same time, data from in vivo and in vitro CRC models reveal promising therapeutic applications through miRNA inhibition and miRNA delivery.
Keywords: Cancer diagnosis, colorectal cancer, microRNA, oncogene, therapy, tumor suppressor.
Current Pharmaceutical Biotechnology
Title:MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Volume: 15 Issue: 5
Author(s): Antonios N. Gargalionis, Efthimia K. Basdra and Athanasios G. Papavassiliou
Affiliation:
Keywords: Cancer diagnosis, colorectal cancer, microRNA, oncogene, therapy, tumor suppressor.
Abstract: MicroRNAs (miRNAs) are small, non-coding RNAs that can post-transcriptionally regulate gene expression via messenger RNA (mRNA) targeting. During the past few years several miRNA groups emerged as critical components of developmental and pathological processes, among them being cancer. In colorectal cancer (CRC) specifically, numerous miRNA molecules have been identified up- or downregulated functioning as tumor-specific markers with oncogenic and tumor-suppressive properties. Their dysregulation impacts impaired cellular processes such as cell proliferation, apoptosis, angiogenesis, invasion and metastasis. The detection of extracellular miRNAs in plasma and fecal samples of CRC patients tends to provide novel, non-invasive biomarkers in favor of CRC diagnosis and, at the same time, data from in vivo and in vitro CRC models reveal promising therapeutic applications through miRNA inhibition and miRNA delivery.
Export Options
About this article
Cite this article as:
Gargalionis N. Antonios, Basdra K. Efthimia and Papavassiliou G. Athanasios, MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications, Current Pharmaceutical Biotechnology 2014; 15 (5) . https://dx.doi.org/10.2174/1389201015666140519123609
DOI https://dx.doi.org/10.2174/1389201015666140519123609 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Challenges for Drug Discovery - A Case Study of Urokinase Receptor Inhibition
Combinatorial Chemistry & High Throughput Screening Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells
Current Cancer Drug Targets Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Rationale and Design of the CAN Study: an RCT of Survival after Propofol- or Sevoflurane-based Anesthesia for Cancer Surgery
Current Pharmaceutical Design Direct Selection of cDNAs from Filamentous Phage Surface Display Libraries: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection
Current HIV Research Cytochrome P450 2A6 Phenotyping Using Dietary Caffeine Salivary Metabolite Ratios and Genotyping Using Blood on Storage Cards in Non-smoking Japanese Volunteers
Drug Metabolism Letters Increasing Sensitivity to Radiotherapy and Chemotherapy by Using Novel Biological Agents that Alter the Tumor Microenvironment
Current Molecular Medicine Application of Biological Study for Met Expression to Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Anti-Cancer Agents in Medicinal Chemistry Role of the Renin-Angiotensin System in Gynecologic Cancers
Current Cancer Drug Targets Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Current Topics in Medicinal Chemistry Peptido-Targeting of the Mitochondrial Transition Pore Complex for Therapeutic Apoptosis Induction
Current Pharmaceutical Design Lactobacillus rhamnosus GG Influences Polyamine Metabolism in HGC-27 Gastric Cancer Cell Line: A Strategy Toward Nutritional Approach to Chemoprevention of Gastric Cancer
Current Pharmaceutical Design